Acutaas Chemicals Limited (BOM:543349)
India · Delayed Price · Currency is INR | Market Cap | 259.45B +126.5% |
| Revenue (ttm) | 14.62B +40.9% |
| Net Income | 3.86B +104.3% |
| EPS | 46.98 +102.6% |
| Shares Out | n/a |
| PE Ratio | 67.18 |
| Forward PE | 52.67 |
| Dividend | 1.50 (0.05%) |
| Ex-Dividend Date | Sep 18, 2025 |
| Volume | 70,718 |
| Open | 3,200.05 |
| Previous Close | 3,210.50 |
| Day's Range | 3,161.00 - 3,250.15 |
| 52-Week Range | 1,290.05 - 3,735.00 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 2,973.40 (-6.16%) |
| Earnings Date | Jul 24, 2026 |
About Acutaas Chemicals
Acutaas Chemicals Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally. The company offers pharma intermediates for use in regulated and generic active pharmaceutical ingredients for anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson’s, antidepressant, and anticoagulant applications. It also provides specialty chemicals for use in battery chemicals, personal care, agrochemicals, coatings, electronics, and industrial processes; photoresist... [Read more]
Financial Performance
In fiscal year 2026, Acutaas Chemicals's revenue was 13.39 billion, an increase of 33.02% compared to the previous year's 10.07 billion. Earnings were 3.56 billion, an increase of 124.46%.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for 543349 stock is "Buy." The 12-month stock price target is ₹2,973, which is a decrease of -6.16% from the latest price.
News
Acutaas Chemicals Transcript: Q1 26/27
Q1 FY 2027 saw 59.1% YoY revenue growth, margin expansion, and strong demand in pharma intermediates and battery chemicals. New plants and product launches are set to drive further growth, with 25% revenue growth guidance and stable margins for FY 2027.
Acutaas Chemicals Quarterly report: Q1 2027
Acutaas Chemicals has published its Q1 2027 quarterly earnings report on July 24, 2026.
Acutaas Chemicals Slides: Q1 2027
Acutaas Chemicals has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 24, 2026.
Acutaas Chemicals Slides: Corporate presentation
Acutaas Chemicals has posted slides in relation to its latest quarterly earnings report, which was published on May 16, 2026.
Acutaas Chemicals Transcript: Q4 25/26
Record FY26 revenue and PAT driven by strong growth in pharma intermediates, specialty, and battery chemicals. FY27 guidance targets 25-28% revenue growth with stable margins, supported by robust order book and new product launches.
Acutaas Chemicals Quarterly report: Q4 2026
Acutaas Chemicals has published its Q4 2026 quarterly earnings report on April 30, 2026.
Acutaas Chemicals Slides: Q4 2026
Acutaas Chemicals has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on April 30, 2026.
Acutaas Chemicals Transcript: Q3 25/26
Q3 FY 2026 saw revenue rise 43% year-over-year to INR 393.2 crore, with record-high margins and profit after tax exceeding INR 100 crore. Upgraded FY 2026 guidance projects 30% revenue growth and 32–35% EBITDA margin, driven by strong CDMO, battery, and semiconductor segments.
Acutaas Chemicals Quarterly report: Q3 2026
Acutaas Chemicals has published its Q3 2026 quarterly earnings report on January 28, 2026.
Acutaas Chemicals Slides: Q3 2026
Acutaas Chemicals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on January 28, 2026.
Acutaas Chemicals Transcript: Q2 25/26
Q2 FY26 saw strong revenue and margin growth, led by pharmaceutical intermediates and CDMO. Battery chemicals and semiconductor verticals are set to drive future growth, with major CapEx projects on track. EBITDA margin guidance is raised to 28%-30%, supported by improved product mix and operational efficiency.
Acutaas Chemicals Quarterly report: Q2 2026
Acutaas Chemicals has published its Q2 2026 quarterly earnings report on October 17, 2025.
Acutaas Chemicals Slides: Q2 2026
Acutaas Chemicals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on October 17, 2025.